绝经前双侧输卵管卵巢切除术与内侧颞叶神经退行性变的关联
该巢式病例对照研究纳入1988至2007年接受双侧输卵管卵巢切除术(BSO)的绝经前女性及对照,发现BSO组杏仁核体积更小、海马旁回-内嗅皮质更薄、内嗅白质各向异性更低,整体认知状态无差异,作者认为BSO相关激素骤变可能与日后内侧颞叶结构异常有关。
要点
- 绝经前BSO与日后杏仁核体积缩小相关(中位数1.74 vs 2.15 cm³,P < .001)。
- BSO组海马旁回-内嗅皮质更薄(3.91 vs 3.97 mm,P = .046)。
- BSO组内嗅白质各向异性更低(0.19 vs 0.22,P = .03)。
核心结论
- 绝经前女性BSO相关的激素骤变可能日后导致内侧颞叶结构异常。
- 需纵向评估以确定是否随后出现认知下降。
研究设计与样本
- 巢式病例对照研究,对象来自明尼苏达州奥姆斯特德县基于人群的Mayo Clinic卵巢切除术与衰老队列研究-2(MOA-2)及Mayo Clinic衰老研究(MCSA)。
- 纳入1988至2007年接受BSO的女性及两队列交集对照,完成神经心理评估、MRI和PiB-PET者进入分析。
- 数据分析于2017年11月至2018年8月进行。
主要发现
- 共招募41例BSO女性和49例对照;BSO组1例因卵巢恶性肿瘤诊断排除,对照组6例入组后接受BSO排除;最终20例对照和23例BSO女性完成全部检查。
- 影像时中位年龄BSO组65(62-68)岁,对照组63(60-66)岁。
- 杏仁核体积BSO组中位数1.74(1.59-1.91)cm³小于对照组2.15(2.05-2.37)cm³,P < .001。
- 海马旁回-内嗅皮质厚度BSO组中位数3.91(3.64-4.00)mm薄于对照组3.97(3.89-4.28)mm,P = .046。
- 内嗅白质各向异性BSO组中位数0.19(0.18-0.22)低于对照组0.22(0.20-0.23),P = .03;整体认知状态测试两组无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is an increased risk of cognitive impairment or dementia in women who undergo bilateral salpingo-oophorectomy (BSO) before menopause. However, data are lacking on the association of BSO before menopause with imaging biomarkers that indicate medial temporal lobe neurodegeneration and Alzheimer disease pathophysiology. OBJECTIVE: To investigate medial temporal lobe structure, white matter lesion load, and β-amyloid deposition in women who underwent BSO before age 50 years and before reaching natural menopause. DESIGN, SETTING, AND PARTICIPANTS: This nested case-control study of women in the population-based Mayo Clinic Cohort Study of Oophorectomy and Aging-2 (MOA-2) and in the Mayo Clinic Study of Aging (MCSA) in Olmsted County, Minnesota, included women who underwent BSO from 1988 through 2007 and a control group from the intersection of the 2 cohorts. Women who underwent BSO and control participants who underwent a neuropsychological evaluation, magnetic resonance imaging (MRI), and Pittsburgh compound B positron emission tomography (PiB-PET) were included in the analysis. Data analysis was performed from November 2017 to August 2018. EXPOSURE: Bilateral salpingo-oophorectomy in premenopausal women who were younger than 50 years. MAIN OUTCOMES AND MEASURES: Cortical β-amyloid deposition on PiB-PET scan was calculated using the standard uptake value ratio. White matter hyperintensity volume and biomarkers for medial temporal lobe neurodegeneration (eg, amygdala volume, hippocampal volume, and parahippocampal-entorhinal cortical thickness) on structural MRI and entorhinal white matter fractional anisotropy on diffusion tensor MRI were also measured. RESULTS: Forty-one women who underwent BSO and 49 control participants were recruited. One woman was excluded from the BSO group after diagnosis of an ovarian malignant condition, and 6 women were excluded from the control group after undergoing BSO after enrollment. Twenty control participants and 23 women who had undergone BSO completed all examinations. The median (interquartile range [IQR]) age at imaging was 65 (62-68) years in the BSO group and 63 (60-66) years in the control group. Amygdala volume was smaller in the BSO group (median [IQR], 1.74 [1.59-1.91] cm3) than the control group (2.15 [2.05-2.37] cm3; P < .001). The parahippocampal-entorhinal cortex was thinner in the BSO group (median [IQR], 3.91 [3.64-4.00] mm) than the control group (3.97 [3.89-4.28] mm; P = .046). Entorhinal white matter fractional anisotropy was lower in the BSO group (median [IQR], 0.19 [0.18-0.22]) than the control group (0.22 [0.20-0.23]; P = .03). Women were treated with estrogen in both groups (BSO, n = 22 of 23 [96%]; control, n = 10 of 19 [53%]). Global cognitive status test results did not differ between the groups. CONCLUSIONS AND RELEVANCE: Abrupt hormonal changes associated with BSO in premenopausal women may lead to medial temporal lobe structural abnormalities later in life. Longitudinal evaluation is needed to determine whether cognitive decline follows.
引用
- Zeydan B, Tosakulwong N, Schwarz CG, et al. Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe Neurodegeneration. JAMA Neurol. 2019. PMID: 30326011. doi:10.1001/jamaneurol.2018.3057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。